title: Construction and comparison of different nanocarriers for co-delivery of cisplatin and curcumin: A synergistic combination nanotherapy for cervical cancer.
abstract: OBJECTIVE
  Co-delivery of two or more drugs into the same cancer cells or tissues in the same nanocarriers provides a new paradigm in cancer treatment. In this study, two kinds of nanocarriers: lipid-polymer hybrid nanoparticles (LPNs) and polymeric nanoparticles (PNPs) were constructed and compared for co-delivery of cisplatin (DDP) and curcumin (CUR).
  
  
  METHODS
  DDP and CUR loaded LPNs (D/C/LPNs) and PNPs (D/C/PNPs) were prepared. Two kinds of nanocarriers were characterized in terms of particle size, zeta potential, drug encapsulation efficiency (EE), and drug release. Their in vitro cytotoxicity and in vivo anti-tumor efficacy was studied on human cervix adenocarcinoma cell line (HeLa cells) and mice bearing cervical cancer model.
  
  
  RESULTS
  Compared with D/C/PNPs, D/C/LPNs showed significantly higher cytotoxicity in vitro. D/C/LPNs also displayed the best antitumor activity than other formulations tested in vivo.
  
  
  CONCLUSIONS
  The results demonstrated that LPNs could improve the anticancer efficacy of drugs to higher levels than PNPs and free drugs, thus could serve as an effective drug system for targeted and synergistic co-delivery nanomedicine for cervical cancer chemotherapy.
authors.affiliation: Department of Pharmacy, Linyi People's Hospital, Linyi, Shandong, PR China.
authors.forename: Changming
authors.initials: C
authors.lastname: Li
authors.affiliation: Department of Pharmacy, Linyi People's Hospital, Linyi, Shandong, PR China.
authors.forename: Xiangcheng
authors.initials: X
authors.lastname: Ge
authors.affiliation: Department of Pharmacy, Linyi People's Hospital, Linyi, Shandong, PR China. Electronic address: wlglyph@163.com.
authors.forename: Liguo
authors.initials: L
authors.lastname: Wang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry; D045744:Cell Line, Tumor; D002626:Chemistry, Pharmaceutical / Q000379:methods; D002945:Cisplatin / Q000008:administration & dosage* / Q000737:chemistry*; D003474:Curcumin / Q000008:administration & dosage* / Q000737:chemistry*; D004337:Drug Carriers / Q000737:chemistry*; D004338:Drug Combinations; D016503:Drug Delivery Systems / Q000379:methods; D065546:Drug Liberation; D005260:Female; D006367:HeLa Cells; D006801:Humans; D008055:Lipids / Q000737:chemistry; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D050997:Nanomedicine / Q000379:methods; D053758:Nanoparticles / Q000737:chemistry*; D010316:Particle Size; D011108:Polymers / Q000737:chemistry; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D004338:Drug Combinations; D008055:Lipids; D011108:Polymers; D003474:Curcumin; D002945:Cisplatin
keywords: Cisplatin; Co-delivery; Curcumin; Lipid-polymer hybrid nanoparticles; Polymeric nanoparticles; Synergistic combination nanotherapy